Brokerages Anticipate Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to Post -$0.54 Earnings Per Share

Analysts expect Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) to report earnings per share of ($0.54) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Bellicum Pharmaceuticals’ earnings. The highest EPS estimate is ($0.39) and the lowest is ($0.63). Bellicum Pharmaceuticals reported earnings of ($0.55) per share in the same quarter last year, which would indicate a positive year over year growth rate of 1.8%. The business is expected to announce its next earnings results on Tuesday, November 5th.

According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full year earnings of ($2.07) per share for the current financial year, with EPS estimates ranging from ($2.28) to ($1.72). For the next financial year, analysts forecast that the firm will report earnings of ($1.50) per share, with EPS estimates ranging from ($2.06) to ($1.04). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Bellicum Pharmaceuticals.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.58) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.04). Bellicum Pharmaceuticals had a negative return on equity of 169.33% and a negative net margin of 4,081.44%. The company had revenue of $1.39 million during the quarter, compared to the consensus estimate of $0.23 million.



BLCM has been the topic of several recent research reports. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Zacks Investment Research upgraded shares of Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.25 target price on the stock in a report on Thursday, August 8th.

Bellicum Pharmaceuticals stock traded down $0.01 during midday trading on Thursday, hitting $1.03. 2,005 shares of the company’s stock were exchanged, compared to its average volume of 450,169. The company has a current ratio of 2.67, a quick ratio of 2.67 and a debt-to-equity ratio of 1.23. Bellicum Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $7.26. The business’s 50-day moving average price is $1.55. The firm has a market cap of $47.41 million, a P/E ratio of -0.43 and a beta of 1.48.

A number of institutional investors have recently modified their holdings of the business. Raymond James & Associates grew its holdings in Bellicum Pharmaceuticals by 21.4% during the 4th quarter. Raymond James & Associates now owns 29,507 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 5,205 shares in the last quarter. BNP Paribas Arbitrage SA lifted its position in shares of Bellicum Pharmaceuticals by 78.9% during the first quarter. BNP Paribas Arbitrage SA now owns 12,567 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 5,544 shares during the last quarter. Knott David M lifted its position in shares of Bellicum Pharmaceuticals by 13.2% during the first quarter. Knott David M now owns 126,127 shares of the biopharmaceutical company’s stock valued at $425,000 after buying an additional 14,700 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Bellicum Pharmaceuticals during the fourth quarter valued at about $48,000. Finally, Eagle Ridge Investment Management purchased a new stake in shares of Bellicum Pharmaceuticals during the first quarter valued at about $67,000. Institutional investors own 58.83% of the company’s stock.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen.

Featured Article: Equity Income

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.